<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pathogenesis of ascites in patients with cirrhosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pathogenesis of ascites in patients with cirrhosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pathogenesis of ascites in patients with cirrhosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bruce A Runyon, MD, FAASLD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Keith D Lindor, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen M Robson, MD, MBA, FACG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 29, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ascites is defined as the pathologic accumulation of fluid in the peritoneal cavity. It is the most common complication of cirrhosis, which is the most common cause of ascites in the United States, accounting for approximately 85 percent of cases. Within 10 years after the diagnosis of compensated cirrhosis, about 50 percent of patients will have developed ascites [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The development of ascites is the final consequence of a series of anatomic, pathophysiologic, and biochemical abnormalities occurring in patients with cirrhosis. The two older theories of ascites formation, the underfill theory [
         <a href="#rid2">
          2
         </a>
         ] and the overflow theory [
         <a href="#rid3">
          3
         </a>
         ], appear to be relevant at different stages of the natural history of cirrhosis [
         <a href="#rid4">
          4
         </a>
         ]. However, the most recent theory, the arterial vasodilation hypothesis, appears to match best with the actual hemodynamic data and has become the most widely accepted theory [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         The formation of ascites is governed by the same principles as edema formation at other sites: net capillary permeability and the hydraulic and oncotic pressure gradients. (See
         <a class="medical medical_review" href="/z/d/html/2309.html" rel="external">
          "Pathophysiology and etiology of edema in adults"
         </a>
         .)
        </p>
        <p>
         Gut lymphatics may play a more important role than previously recognized [
         <a href="#rid6">
          6
         </a>
         ]. Lymphangiectasia becomes prominent and abdominal lymph production can increase by 30-fold.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PORTAL HYPERTENSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The development of portal hypertension (PHT) is the first step toward fluid retention in the setting of cirrhosis. Patients with cirrhosis but without PHT do not develop ascites or edema [
         <a href="#rid7">
          7
         </a>
         ]. A portal pressure &gt;12 mmHg appears to be required for fluid retention [
         <a href="#rid7">
          7,8
         </a>
         ]; on the other hand, ascites will usually disappear if portal pressure is reduced below 12 mmHg (eg, after a surgical or radiologic portosystemic shunt) [
         <a href="#rid9">
          9
         </a>
         ]. Sinusoidal hypertension appears to be required for fluid retention to occur; presinusoidal portal hypertension, as in portal vein thrombosis, does not result in ascites formation in the absence of another predisposing factor.
        </p>
        <p>
         PHT leads to profound changes in the splanchnic circulation. Although it was formerly thought that PHT was due solely to a mechanical obstruction to portal flow, data from animal models provide evidence for a component of increased portal venous inflow as a consequence of splanchnic arterial vasodilation [
         <a href="#rid10">
          10,11
         </a>
         ].
        </p>
        <p>
         Patients with cirrhosis and clinically significant PHT have several circulatory, vascular, functional, and biochemical abnormalities that contribute to the pathogenesis of fluid retention (
         <a class="graphic graphic_table graphicRef62128" href="/z/d/graphic/62128.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Vasodilation and hyperdynamic circulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with cirrhosis and ascites usually have a marked reduction in systemic vascular resistance (SVR) and in mean arterial pressure (MAP) plus an increase in cardiac output [
         <a href="#rid12">
          12-14
         </a>
         ]. These abnormalities result in a hyperdynamic circulation which can be found in patients and experimental animals with cirrhosis before the development of ascites [
         <a href="#rid15">
          15-17
         </a>
         ].
        </p>
        <p>
         The vascular territory where the reduced SVR is most obvious is the arterial splanchnic circulation [
         <a href="#rid5">
          5
         </a>
         ]. The presence of this abnormality in other vascular territories is less obvious and the subject of controversy [
         <a href="#rid16">
          16,18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Mechanisms of vasodilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Considerable effort has been made to elucidate the exact mechanism(s) of arterial vasodilation and the hyperdynamic circulation of cirrhosis (
         <a class="graphic graphic_algorithm graphicRef81659" href="/z/d/graphic/81659.html" rel="external">
          algorithm 1
         </a>
         ). Anatomic and functional liver-related causes have been considered in order to explain the presence of vasodilation.
        </p>
        <p>
         The opening of portasystemic collaterals, a frequent finding in cirrhosis, helps explain the presence of vasodilation [
         <a href="#rid13">
          13
         </a>
         ]. The performance of portocaval shunts in these patients further decreases SVR [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Although portosystemic collaterals may contribute, most of the studies which have examined the vasodilation in patients with cirrhosis have focused on increased levels of circulating vasodilators. Glucagon has been one of the most widely studied [
         <a href="#rid19">
          19,20
         </a>
         ], although its role in the pathogenesis of vasodilation has not been precisely defined [
         <a href="#rid7">
          7,13
         </a>
         ]. Other vasodilators have been considered, such as vasoactive intestinal peptide, substance P, platelet-activating-factor or prostaglandins [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Increased synthesis of systemic prostacyclin has been observed in patients with cirrhosis even before they develop ascites [
         <a href="#rid21">
          21
         </a>
         ]. The synthesis of renal prostacyclin is increased in these patients [
         <a href="#rid22">
          22
         </a>
         ] and contributes to maintenance of the glomerular filtration rate (as evidenced by reductions in glomerular filtration rate and renal plasma flow following the administration of a nonsteroidal antiinflammatory drug) [
         <a href="#rid23">
          23
         </a>
         ]. Renal prostaglandin synthesis decreases with advanced liver disease and may contribute to the marked renal vasoconstriction in patients with hepatorenal syndrome [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2308.html" rel="external">
          "Hepatorenal syndrome", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p>
         Patients with cirrhosis but without portal hypertension (eg, patients after portasystemic shunt) also show increased levels of systemic prostacyclin [
         <a href="#rid24">
          24
         </a>
         ]. It is possible that this activation is related to the presence of endotoxemia, since selective intestinal decontamination with nonabsorbable antibiotics significantly decreases the synthesis of systemic prostacyclin [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Although the above factors may play a contributory role, much of the recent literature has focused on the possible role of nitric oxide (NO) [
         <a href="#rid25">
          25,26
         </a>
         ]. The following observations suggest that NO is the primary mediator of vasodilation in cirrhosis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The activity of endothelial NO synthase (which promotes the synthesis of NO from L-arginine) is increased in the arterial vessels of cirrhotic rats with ascites [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The serum levels of nitrite and nitrate, an index of in vivo NO synthesis, are significantly higher in patients with cirrhosis than in controls [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inhibition of the synthesis of NO in rats with cirrhosis significantly increases the arterial pressure and SVR, decreases the cardiac index [
         <a href="#rid29">
          29
         </a>
         ] and reverses the impaired response to vasopressors [
         <a href="#rid30">
          30,31
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The possible factors responsible for the increased NO synthesis in cirrhosis have been intensively studied. Nitric oxide production may be stimulated by endotoxin or other bacterial products, such as bacterial DNA from the gastrointestinal tract, which are less efficiently cleared due to portal-systemic shunting and decreased reticuloendothelial cell function in cirrhosis. The increased synthesis of NO is mediated by both the endothelial [
         <a href="#rid32">
          32
         </a>
         ] and inducible forms [
         <a href="#rid33">
          33
         </a>
         ]. Interestingly, it has been shown in animal models of cirrhosis that bacterial translocation may be present prior to the development of ascites, providing a rationale for the increased synthesis of NO even before ascites is present [
         <a href="#rid34">
          34
         </a>
         ]. The following observations support the role of endotoxin or other bacterial products in the stimulation of NO production (
         <a class="graphic graphic_algorithm graphicRef81659" href="/z/d/graphic/81659.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid25">
          25,28
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         NO concentrations in blood collected from portal vein are higher than those of peripheral veins [
         <a href="#rid35">
          35
         </a>
         ] and serum NO concentrations parallel serum bacterial DNA concentrations [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A significant correlation has been noted between serum nitrite and nitrate levels and endotoxin [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oral administration of the antibiotic
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          colistin
         </a>
         to patients with cirrhosis significantly reduces plasma endotoxin levels and the serum concentration of nitrite and nitrate [
         <a href="#rid35">
          35
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9710" href="/z/d/drug information/9710.html" rel="external">
          norfloxacin
         </a>
         increases systemic vascular resistance and decreases plasma renin in a subgroup of patients with ascites [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fragments of bacterial DNA in blood and ascitic fluid have been described in one-third of patients with cirrhosis and ascites and up to two-thirds of patients with refractory ascites [
         <a href="#rid38">
          38-40
         </a>
         ]. Bacterial DNA is rarely present in patients with cirrhosis who do not have ascites. Bacterial DNA induces the synthesis of nitric oxide by peritoneal macrophages, suggesting that it may be related to the hemodynamic derangement observed in patients with advanced cirrhosis [
         <a href="#rid33">
          33
         </a>
         ]. In addition, bacterial DNA may further impair the endothelial dysfunction commonly found in this setting [
         <a href="#rid41">
          41
         </a>
         ]. Some data suggest that its presence is correlated with a poor prognosis, but more studies are needed [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Animal models of cirrhosis have shown that the presence of bacterial DNA in biological fluids is invariably associated with its simultaneous presence in mesenteric lymph nodes, either as viable (culture-positive) or nonviable (culture-negative) forms [
         <a href="#rid43">
          43-46
         </a>
         ]. These observations have led to the modification of the concept of bacterial translocation to include the presence of bacterial products in mesenteric lymph nodes, and not only a positive culture.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          CONSEQUENCES OF VASODILATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The progressive vasodilation seen in cirrhosis leads to the activation of endogenous vasoconstrictors, sodium and water retention, and increasing renal vasoconstriction.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Activation of endogenous vasoconstrictor agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         The reduction in pressure (or stretch) at the carotid and renal baroreceptors induced by cirrhotic vasodilation results in activation of the sodium-retaining neurohumoral mechanisms in an attempt to restore perfusion pressure to normal (
         <a class="graphic graphic_algorithm graphicRef81659" href="/z/d/graphic/81659.html" rel="external">
          algorithm 1
         </a>
         ). These include the renin-angiotensin-aldosterone system, sympathetic nervous system, and antidiuretic hormone (vasopressin). The secretion of these "hypovolemic" hormones is proportional to the severity of the hemodynamic insufficiency (
         <a class="graphic graphic_figure graphicRef74244" href="/z/d/graphic/74244.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid47">
          47-49
         </a>
         ].
        </p>
        <p>
         The net effect is avid sodium and water retention because the patient is effectively volume depleted even though extracellular sodium stores, the plasma volume, and the cardiac output are increased.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Sodium retention
         </span>
         <span class="headingEndMark">
          —
         </span>
         The retention of sodium and water increases the plasma volume. If this were adequate to refill the intravascular space, the activity of the endogenous vasoconstrictor systems would decrease, with a progressive normalization of the excretion of sodium and water (
         <a class="graphic graphic_algorithm graphicRef80443" href="/z/d/graphic/80443.html" rel="external">
          algorithm 2
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]. However, impaired sodium excretion after a
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         load [
         <a href="#rid50">
          50
         </a>
         ] and a reduction in central blood volume [
         <a href="#rid51">
          51
         </a>
         ] have been demonstrated in patients with cirrhosis who have not yet developed ascites. This unstable equilibrium can be affected by infections, drugs, or progressive impairment in liver function. In advanced disease, sodium excretion often falls to less than 10 mEq/day [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Thus, sodium retention is a sensitive marker of the overall status of the patient with cirrhosis. A significant nonlinear relationship has been identified between urinary sodium excretion and the aminopyrine breath test, a measurement of true liver function [
         <a href="#rid52">
          52
         </a>
         ]; the presence of sodium retention was indicative of at least a 50 percent reduction in liver function [
         <a href="#rid52">
          52
         </a>
         ]. True liver function usually drops below 60 percent before ascites forms according to a newer measure of liver function, the perfused hepatic mass or quantitative liver-spleen scan [
         <a href="#rid53">
          53
         </a>
         ]. This nuclear medicine-based test received approval from the US Food and Drug Administration in January of 2015.
        </p>
        <p>
         Fluid overload is an important landmark in the natural history of these patients, and the degree of sodium retention is inversely related to survival. In one series, for example, patients with ascites and urinary sodium excretion below 10 mEq/day had a mean survival as low as five to six months, in comparison to over two years in those with ascites and a higher rate of sodium excretion [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Water retention
         </span>
         <span class="headingEndMark">
          —
         </span>
         Water excretion is usually normal in patients with cirrhosis before the development of ascites and then becomes increasingly impaired as the liver disease progresses. This abnormality is largely related to the increased release of antidiuretic hormone (ADH) described above [
         <a href="#rid47">
          47-49
         </a>
         ], since suppression of ADH release is required to excrete a water load. The pathogenetic importance of ADH in water retention in cirrhosis has been demonstrated in rats with cirrhosis in which the administration of an ADH receptor antagonist restores near normal water excretory ability [
         <a href="#rid54">
          54
         </a>
         ]. The inability to excrete water regularly leads to the development of hyponatremia and hypoosmolality [
         <a href="#rid55">
          55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2326.html" rel="external">
          "Hyponatremia in patients with cirrhosis"
         </a>
         .)
        </p>
        <p>
         Thus, patients with cirrhosis and ascites usually demonstrate urinary sodium retention, increased total body sodium, and dilutional hyponatremia. It can be challenging to explain to patients and their families (and even to some clinicians) that the hyponatremia does not indicate a deficiency of sodium.
        </p>
        <p>
         Because the increase in ADH secretion (and therefore the degree of water retention) is roughly proportional to the severity of the cirrhosis (
         <a class="graphic graphic_figure graphicRef74244" href="/z/d/graphic/74244.html" rel="external">
          figure 1
         </a>
         ), the degree of hyponatremia parallels the severity of the liver disease and is, along with the degree of sodium retention, of prognostic value. The severity of hyponatremia correlates with worsening survival [
         <a href="#rid56">
          56-59
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Renal vasoconstriction
         </span>
         <span class="headingEndMark">
          —
         </span>
         The activation of vasoconstrictor systems tends to reduce renal blood flow [
         <a href="#rid60">
          60
         </a>
         ]. Renal perfusion may initially be maintained due to vasodilators such as prostaglandins and perhaps nitric oxide (
         <a class="graphic graphic_algorithm graphicRef80443" href="/z/d/graphic/80443.html" rel="external">
          algorithm 2
         </a>
         ). However, the natural progression of liver disease overcomes these protective mechanisms, leading to progressive renal hypoperfusion, a gradual decline in the glomerular filtration rate, and, in some patients, the hepatorenal syndrome [
         <a href="#rid16">
          16,61
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2308.html" rel="external">
          "Hepatorenal syndrome", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p>
         The importance of splanchnic vasodilation in the genesis of renal ischemia has been indirectly illustrated by the response to ornipressin and
         <a class="drug drug_general" data-topicid="139628" href="/z/d/drug information/139628.html" rel="external">
          terlipressin
         </a>
         , analogs of antidiuretic hormone (arginine vasopressin) that are preferential splanchnic vasoconstrictors [
         <a href="#rid11">
          11,62,63
         </a>
         ]. In patients with advanced cirrhosis, the administration of ornipressin or terlipressin raised the mean arterial pressure, increased renal blood flow, glomerular filtration rate, and urinary sodium excretion and volume. (See
         <a class="medical medical_review" href="/z/d/html/2308.html" rel="external">
          "Hepatorenal syndrome", section on 'Terlipressin plus albumin where available'
         </a>
         .)
        </p>
        <p>
         The reduction in glomerular filtration rate in patients with liver disease is often masked clinically. Both urea and creatinine production may be substantially reduced in this setting, due to the liver disease and to decreased muscle mass. The net effect is that a serum creatinine concentration that appears to be within the normal range (1 to 1.3 mg/dL or 88 to 115 micromol/L) may, depending primarily upon muscle mass, be associated with a glomerular filtration rate that ranges from as low as 20 to 60 mL/min to a clearly normal value above 100 mL/min [
         <a href="#rid64">
          64,65
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15625663">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Background
         </strong>
         – Ascites is defined as the pathologic accumulation of fluid in the peritoneal cavity. It is most commonly caused by cirrhosis. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Development of portal hypertension
         </strong>
         – The development of portal hypertension (PHT) is the first step toward fluid retention in the setting of cirrhosis. Patients with cirrhosis but without PHT do not develop ascites or edema. A portal pressure &gt;12 mmHg appears to be required for fluid retention. (See
         <a class="local">
          'Portal hypertension'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with cirrhosis and clinically significant PHT have several circulatory, vascular, functional, and biochemical abnormalities that contribute to the pathogenesis of fluid retention (
         <a class="graphic graphic_table graphicRef62128" href="/z/d/graphic/62128.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Portal hypertension'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4043070728">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff thank Dr. José Such, MD, PhD for his contributions as author to prior versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Ginés P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SHERLOCK S, SHALDON S. The aetiology and management of ascites in patients with hepatic cirrhosis: a review. Gut 1963; 4:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieberman FL, Denison EK, Reynolds TB. The relationship of plasma volume, portal hypertension, ascites, and renal sodium retention in cirrhosis: The overflow theory of ascites formation. Ann N Y Acad Sci 1970; 170:292.
          </a>
         </li>
         <li class="breakAll">
          Runyon, BA. Ascites and spontaneous bacterial peritonitis. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease, Feldman, M, Friedman, LS, Brandt, LJ (Eds), WB Saunders, Philadelphia 2016. p.1553.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solà E, Ginès P. Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. J Hepatol 2010; 53:1135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juneja P, Tripathi DM, Kaur S. Revisiting the gut-liver axis: gut lymphatic system in liver cirrhosis and portal hypertension. Am J Physiol Gastrointest Liver Physiol 2022; 322:G473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ginès P, Fernández-Esparrach G, Arroyo V, Rodés J. Pathogenesis of ascites in cirrhosis. Semin Liver Dis 1997; 17:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morali GA, Sniderman KW, Deitel KM, et al. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites? J Hepatol 1992; 16:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reichle FA, Owen OE. Hemodynamic patterns in human hepatic cirrhosis: a prospective randomized study of the hemodynamic sequelae of distal splenorenal (Warren) and mesocaval shunts. Ann Surg 1979; 190:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vorobioff J, Bredfeldt JE, Groszmann RJ. Increased blood flow through the portal system in cirrhotic rats. Gastroenterology 1984; 87:1120.
          </a>
         </li>
         <li class="breakAll">
          Cardenas A, Gines P. Pathobiology, Evaluation, and Treatment. In: Portal Hypertension, Sanyal AJ, Shah VH (Eds), Humana Press, 2005. p.65.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abelmann WH. Hyperdynamic circulation in cirrhosis: a historical perspective. Hepatology 1994; 20:1356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol 2007; 46:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           European Association for the Study of the Liver. Electronic address:
           <span class="__cf_email__" data-cfemail="e28783918e8d84848b8187a28783918e8d84848b8187cc8797">
            [email protected]
           </span>
           , European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           KOWALSKI HJ, ABELMANN WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953; 32:1025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandez-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989; 97:1304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bosch J, Arroyo V, Betriu A, et al. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology 1980; 78:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maroto A, Ginès P, Arroyo V, et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 1993; 17:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benoit JN, Granger DN. Splanchnic hemodynamics in chronic portal hypertension. Semin Liver Dis 1986; 6:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kravetz D, Arderiu M, Bosch J, et al. Hyperglucagonemia and hyperkinetic circulation after portocaval shunt in the rat. Am J Physiol 1987; 252:G257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guarner C, Colina I, Guarner F, et al. Renal prostaglandins in cirrhosis of the liver. Clin Sci (Lond) 1986; 70:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guarner F, Guarner C, Prieto J, et al. Increased synthesis of systemic prostacyclin in cirrhotic patients. Gastroenterology 1986; 90:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong F, Massie D, Hsu P, Dudley F. Indomethacin-induced renal dysfunction in patients with well-compensated cirrhosis. Gastroenterology 1993; 104:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guarner C, Soriano G, Such J, et al. Systemic prostacyclin in cirrhotic patients. Relationship with portal hypertension and changes after intestinal decontamination. Gastroenterology 1992; 102:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006; 43:S121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ros J, Jiménez W, Lamas S, et al. Nitric oxide production in arterial vessels of cirrhotic rats. Hepatology 1995; 21:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18:1139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clària J, Jiménez W, Ros J, et al. Pathogenesis of arterial hypotension in cirrhotic rats with ascites: role of endogenous nitric oxide. Hepatology 1992; 15:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sieber CC, Lopez-Talavera JC, Groszmann RJ. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology 1993; 104:1750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology 1992; 103:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiest R, Das S, Cadelina G, et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francés R, Muñoz C, Zapater P, et al. Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut 2004; 53:860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Úbeda M, Muñoz L, Borrero MJ, et al. Critical role of the liver in the induction of systemic inflammation in rats with preascitic cirrhosis. Hepatology 2010; 52:2086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Battista S, Bar F, Mengozzi G, et al. Systemic and portal nitric oxide and endothelin-1 levels in cirrhotic patients. J Hepatol 1995; Suppl 1:73 (A).
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francés R, Zapater P, González-Navajas JM, et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 2008; 47:978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albillos A, de la Hera A, González M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angeli P, Brun P, Cesari M, et al. Prevalence of bacteria DNA in patients with cirrhosis and refractory ascites and its role in the development of caridac and renal dysfunction. Hepatology 2010; 52:342A (abstract).
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Such J, Francés R, Muñoz C, et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 2002; 36:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francés R, Benlloch S, Zapater P, et al. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology 2004; 39:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellot P, García-Pagán JC, Francés R, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology 2010; 52:2044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zapater P, Frances R, Gonzalez-Navajas JM, et al. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology 2010; 48:1924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guarner C, González-Navajas JM, Sánchez E, et al. The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology 2006; 44:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Runyon BA, Squier S, Borzio M. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. J Hepatol 1994; 21:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiest R, Albillos A, Trauner M, et al. Targeting the gut-liver axis in liver disease. J Hepatol 2017; 67:1084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asbert M, Ginès A, Ginès P, et al. Circulating levels of endothelin in cirrhosis. Gastroenterology 1993; 104:1485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henriksen JH, Bendtsen F, Gerbes AL, et al. Estimated central blood volume in cirrhosis: relationship to sympathetic nervous activity, beta-adrenergic blockade and atrial natriuretic factor. Hepatology 1992; 16:1163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arroyo V, Bosch J, Gaya-Beltrán J, et al. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med 1981; 94:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong F, Massie D, Hsu P, Dudley F. Renal response to a saline load in well-compensated alcoholic cirrhosis. Hepatology 1994; 20:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong F, Liu P, Tobe S, et al. Central blood volume in cirrhosis: measurement with radionuclide angiography. Hepatology 1994; 19:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wensing G, Lotterer E, Link I, et al. Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function. Hepatology 1997; 26:1149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Everson GT, Shiffman ML, Hoefs JC, et al. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. Hepatology 2012; 55:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsuboi Y, Ishikawa S, Fujisawa G, et al. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int 1994; 46:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arroyo V, Clària J, Saló J, Jiménez W. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Semin Liver Dis 1994; 14:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papadakis MA, Fraser CL, Arieff AI. Hyponatraemia in patients with cirrhosis. Q J Med 1990; 76:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heuman DM, Abou-Assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40:802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biggins SW, Rodriguez HJ, Bacchetti P, et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005; 41:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sacerdoti D, Bolognesi M, Merkel C, et al. Renal vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography. Hepatology 1993; 17:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BALDUS WP, FEICHTER RN, SUMMERSKILL WH. THE KIDNEY IN CIRRHOSIS. I. CLINICAL AND BIOCHEMICAL FEATURES OF AZOTEMIA IN HEPATIC FAILURE. Ann Intern Med 1964; 60:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guevara M, Ginès P, Fernández-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2010; 25:880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papadakis MA, Arieff AI. Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. Am J Med 1987; 82:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 2010; 52:605.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1259 Version 22.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3804191" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Compensated cirrhosis: natural history and prognostic factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13977164" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The aetiology and management of ascites in patients with hepatic cirrhosis: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The relationship of plasma volume, portal hypertension, ascites, and renal sodium retention in cirrhosis: The overflow theory of ascites formation
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The relationship of plasma volume, portal hypertension, ascites, and renal sodium retention in cirrhosis: The overflow theory of ascites formation
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20850887" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Renal and circulatory dysfunction in cirrhosis: current management and future perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35195034" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Revisiting the gut-liver axis: gut lymphatic system in liver cirrhosis and portal hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9308123" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Pathogenesis of ascites in cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1484164" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/314787" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Hemodynamic patterns in human hepatic cirrhosis: a prospective randomized study of the hemodynamic sequelae of distal splenorenal (Warren) and mesocaval shunts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6479534" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Increased blood flow through the portal system in cirrhotic rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6479534" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Increased blood flow through the portal system in cirrhotic rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7927272" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Hyperdynamic circulation in cirrhosis: a historical perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17391799" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Vascular endothelial dysfunction in cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29653741" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13096569" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The cardiac output at rest in Laennec's cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2676683" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7350041" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8491446" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3544222" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Splanchnic hemodynamics in chronic portal hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3826352" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Hyperglucagonemia and hyperkinetic circulation after portocaval shunt in the rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3516533" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Renal prostaglandins in cirrhosis of the liver.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3510938" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Increased synthesis of systemic prostacyclin in cirrhotic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8440438" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Indomethacin-induced renal dysfunction in patients with well-compensated cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1727763" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Systemic prostacyclin in cirrhotic patients. Relationship with portal hypertension and changes after intestinal decontamination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1706450" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Hyperdynamic circulation in cirrhosis: a role for nitric oxide?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16447289" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7843730" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Nitric oxide production in arterial vessels of cirrhotic rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8225220" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1735539" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Pathogenesis of arterial hypotension in cirrhotic rats with ascites: role of endogenous nitric oxide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8388839" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1612331" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10545521" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15138214" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21105108" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Critical role of the liver in the induction of systemic inflammation in rats with preascitic cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Systemic and portal nitric oxide and endothelin-1 levels in cirrhotic patients
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18306221" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12500206" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Prevalence of bacteria DNA in patients with cirrhosis and refractory ascites and its role in the development of caridac and renal dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12085357" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14768002" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20979050" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16941689" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7890896" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15723320" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Bacterial translocation (BT) in cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28526488" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Targeting the gut-liver axis in liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8482460" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Circulating levels of endothelin in cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1358779" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Estimated central blood volume in cirrhosis: relationship to sympathetic nervous activity, beta-adrenergic blockade and atrial natriuretic factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7008667" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7927228" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Renal response to a saline load in well-compensated alcoholic cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8294089" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Central blood volume in cirrhosis: measurement with radionuclide angiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9362355" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22030902" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7933842" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8016662" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2217672" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Hyponatraemia in patients with cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15382176" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15690479" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Serum sodium predicts mortality in patients listed for liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15719386" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8428719" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Renal vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14128217" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : THE KIDNEY IN CIRRHOSIS. I. CLINICAL AND BIOCHEMICAL FEATURES OF AZOTEMIA IN HEPATIC FAILURE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9425914" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20074149" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3578363" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20185192" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : The evaluation of renal function and disease in patients with cirrhosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
